Navigation Links
Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip
Date:12/14/2010

NEW YORK, Dec. 14, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Biochip Markets: Microarrays and Lab-on-a-Chip

http://www.reportlinker.com/p0170497/Global-Biochip-Markets-Microarrays-and-Lab-on-a-Chip.html

INTRODUCTION 

STUDY GOALS AND OBJECTIVES

BCC's goal for this study was to determine the status of current and emerging biochip technologies and products, and assess their worldwide growth potential over a 5-year period from 2009 to 2014. We were particularly interested in characterizing the biochip markets for single nucleotide polymorphisms (SNPs), epigenetics, array comparative genome hybridization (aCGH), microRNA (miRNA), proteomics microarray, and lab-on-a-chip (LOAC) markets, which will provide substantial future growth opportunities for biochips. A particular focus of this study is the market for biochip-based diagnostics products. 

Our key objective was to present a comprehensive discussion of where the state-of-the-art is in biochip technologies and the current and future commercial potential for each of the key market segments.

REASONS FOR DOING THE STUDY

Biology is following a path that is reminiscent of the early electronics industry: a miniaturization and large-scale integration process that will revolutionize life-science research, drug discovery and development, medical diagnostics and biotechnology. The ongoing miniaturization and large-scale integration process is encompassed in devices known as biochips, including microarrays and LOAC microfluidic devices. Biochips represent a diverse group
'/>"/>

SOURCE S OF COMPETITIVE ADVANTAGE IN DNA MICROARRAYS 265
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology news :

1. Reportlinker Adds Carbon Dioxide Monitors Report
2. Reportlinker Adds World Dynamic Signature Verification Market Report
3. Reportlinker Adds Proteomics: Technologies and Global Markets Report
4. Reportlinker Adds Biomarkers - technologies, markets and companies
5. Reportlinker Adds Global Biometrics Industry
6. Reportlinker Adds World Biometrics Market
7. Reportlinker Adds Global Flow Cytometers Industry
8. Reportlinker Adds Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics
9. New studies find global warming will have significant economic impacts on Florida coasts
10. Growth in the global carbon budget
11. Global science community to gather in Mozambique
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2014)... 15, 2014 Sandata Technologies, LLC, an ... community-based care, today announced it released a case ... Electronic Visit Verification™ Solution (EVV™)  for Quality Care ... health company founded in 1996 and has five ... The study details the challenges facing ...
(Date:10/15/2014)... German Gauß-Allianz has admitted Johannes Gutenberg University Mainz ... Rhineland-Palatinate science hub continues to maintain a significant ... , "The acceptance of Johannes Gutenberg University ... is a milestone in the national and international ... The state of Rhineland-Palatinate can be proud that ...
(Date:10/15/2014)... Conn. , Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce market releases ... MarketSite in Times Square on Monday October 13 th . ... CTO David Tunnel and angel investor Mr. Chad ... Pereira , CEO of NXT-ID thanked his investors and employees "for ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... Access to Research Careers) Program has announced the travel ... of Chicanos and Native Americans in Science (SACNAS) annual ... These awards are meant to promote the entry of ... mainstream of the basic science community and to encourage ...
... Fox Foundation for Parkinson,s Research and Shake It Up ... Sydney,s Garvan Institute of Medical Research to look at ... Long non-coding RNAs are complex molecules, produced from ... in the body. Unlike conventional genes, they do not ...
... have increasingly relied on the wild and weedy relatives of ... and other traits. But just like all wild plant species, ... decline and extinction due to habitat loss, pollution, and climate ... describe the latest efforts to identify and protect the wild ...
Cached Biology News:Garvan Institute receives grant to research role of long non-coding RNAs in Parkinson's disease 2Protecting the weedy and wild kin of globally important crops 2
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
(Date:10/20/2014)... , October 20, 2014 ... gastrointestinal (GI) disorders and the delivery of care has ... diseases and worrying inequalities in the provision of healthcare ... which was commissioned by United European Gastroenterology (UEG), have ... political and public awareness of the burden of GI ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Partners LLC, announced today that Ellen Teplitzky, an ... support for the pharmaceutical industry, has joined the ... of its legal services practice. NDA Partners ... expert witness and testimony, to top law firms ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... Executive Team, FREMONT, Calif., Sept. 8 ... a novel transdermal,delivery technology, today announced that Gail ... The company also announced several recent,appointments to the ... and president; John M. Vuko, executive vice president ...
... Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it ... trial using intravenous,administration of REOLYSIN(R) in combination with ... neck cancers. The Principal,Investigator is Dr. Monica Mita ... The University of Texas Health Science Center at ...
... Md., Sept. 8 Neuralstem Inc., CEO,Richard Garr, will ... Lateral Sclerosis, or Lou Gehrig,s disease) at the 2008 ... at 2:00 CDT. In a,presentation prior to the panel, ... trial and give an update of the Company,s filing ...
Cached Biology Technology:Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 2Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 3Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 4Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit 2